IPSOGEN
CANCER PROFILER

Press Release

Three New Studies on Genomic Grade

at 33rd Annual San Antonio Breast Cancer Symposium.

Marseille, France, December 7, 2010 - IPSOGEN SA (Alternext: ALIPS) today announced that three studies on Genomic Grade will be presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010, at the Henry B. Gonzalez Convention Center. The Genomic Grade (GGI), a multi-gene expression test, allows improved tumor grading and consequently treatment decisions for women with early invasive hormone receptor positive breast cancer.

Two of these studies result from a collaborative project between Institut Curie, Paris, France and Ipsogen, and document the added value of Genomic Grade in terms of long term prognostication, treatment decision and potential economic impact, compared to classical pathology indexes such as Ki67.
The third study analyses the incorporation of Genomic Grade in the Nottigham Prognostic Index, one of the reference treatment algorithms used for early breast cancer. Replacing Histologic Grade by Genomic Grade, esp. in Histologic Grade 2 cases, leads to the identification of a group of patients with excellent prognosis who could be spared of adjuvant chemotherapy.

Titles, presenters and timings are detailed below (all times are in Central Standard Time):

Poster #P03-10-09

" Genomic Grade Index (GGI): tumor grading performance and prognostic value compared to Ki67 and Mitotic Index in early invasive breast cancer - a reference centre experience. "

Presenter: Fabien Reyal, Department of Surgery, Institut Curie, Paris, France.

Friday, December 10, 2010, 5:30 p.m. – 7:30 p.m.

Poster #P3-10-08

"Combining Genomic Grade and NPI Refines Risk Group Classification"

Presenter: Helene Peyro-Saint-Paul, Ipsogen SA, Marseille, France

Friday, December 10, 2010, 5:30 p.m. – 7:30 p.m.

Poster #P05-13-11

"Medico–Economic Assessment of the Genomic Grade Index on Adjuvant Treatment Strategy in Elston–Ellis Grade 2, Estrogen Receptor Positive, HER2 Negative, Node Negative, Small Size Breast Carcinomas "

Presenter: Fabien Reyal, Department of Surgery, Institut Curie, Paris, France.

Saturday, December 11, 2010, 5:30 p.m. – 7:30 p.m.

About Genomic Grade

The value of tumor grade as one of the key drivers for long term prognosis of Hormone Receptor positive early invasive breast cancer has been widely documented over the last decade and tumor grade is part of all current treatment guidelines and decision algorithms. However, tumor grade, as measured to date by histology, suffers two limitations: variability of assessment across pathology labs, and presence of an intermediate category, Histologic Grade 2, which can represent as much as 50% of Hormone Receptor positive tumors and has a limited informative power for treatment decision making.
The Genomic Grade test has been developed to address these 2 limitations. Proliferation genes are the main component of the selected gene signature. The added value of Genomic Grade to identify high and low grade tumors, esp. in Histologic Grade 2 tumors, has been documented on 3000 cases. Moreover, Genomic Grade is able to separate Luminal A and Luminal B tumors.
Genomic Grade is currently available as Map*Quant*™, an Affymetrix micro-array based assay for research and diagnostic use through an ISO-17025/CLIA Lab Service. A PCR version is currently under development, that will use formalin fixed-parafin embeded specimens.

About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 80 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of 'companion diagnostic' tests.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in molecular profiling of cancers. It continues its efforts to identify develop and commercialise diagnostic tests that will become standard references and will have a significant impact on patients, medical professionals and society.

Ipsogen employed 70 people as of June 30, 2010. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in Stamford, CT, USA.

For more information, visit: www.ipsogen.com

Contacts

IPSOGEN
Vincent Fert
CEO
Tel: + 33 (0)4 9129 3090
fert@ipsogen.com

ATCG Press
Corporate and Product Information

Marielle Bricman
Tel: + 33 (0)4 9125 0785

ipsogen@atcg-partners.com